ReviewCancer research2020
Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers.
Review in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Disruption of the SAGA CORE triggers collateral degradation of KAT2A.Nature communications · 2026Article
- Identification and characterization of a novel transcriptional factor Spt7 involved in conidia formation and mycelium development in Aspergillus niger.BMC microbiology · 2026Article
- SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma.bioRxiv : the preprint server for biology · 2026Article
- MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma.Oncogenesis · 2025Article
- LINC00887 promotes GCN5-dependent H3K27cr level and CRC metastasis via recruitment of YEATS2 and enhancing ETS1 expression.Cell death & disease · 2024Article
- The MYC-MAF-SAGA axis drives oncogenic gene expression in multiple myeloma.Genes & development · 2024Review
- Pharmacological targeting of the cancer epigenome.Nature cancer · 2024Review
- Repression of YEATS2 induces cellular senescence in hepatocellular carcinoma and inhibits tumor growth.Cell cycle (Georgetown, Tex.) · 2024Article
- SGF29 nuclear condensates reinforce cellular aging.Cell discovery · 2023Article
- Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion.Scientific reports · 2023Article
- Cell state-dependent chromatin targeting in NUT carcinoma.Genetics · 2023Article
- Cell state-dependent chromatin targeting in NUT carcinoma.bioRxiv : the preprint server for biology · 2023Article
- MYC: a complex problem.Trends in cell biology · 2023Review
- Integrative analysis of histone acetyltransferase KAT2A in human cancer.Cancer biomarkers : section A of Disease markers · 2023Article
- Article
- Acetylation-dependent SAGA complex dimerization promotes nucleosome acetylation and gene transcription.Nature structural & molecular biology · 2022Article
- Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer.Frontiers in endocrinology · 2022Review
- The biochemical and genetic discovery of the SAGA complex.Biochimica et biophysica acta. Gene regulatory mechanisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Targeting epigenetic regulators, such as histone-modifying enzymes, provides novel strategies for cancer therapy. The GCN5 lysine acetyltransferase (KAT) functions together with MYC both during normal development and in oncogenesis. As transcription factors, MYC family members are difficult to target with small-molecule inhibitors, but the acetyltransferase domain and the bromodomain in GCN5 might provide alternative targets for disruption of MYC-driven functions. GCN5 is part of two distinct multiprotein histone-modifying complexes, SAGA and ATAC. This review summarizes key findings on the roles of SAGA and ATAC in embryo development and in cancer to better understand the functional relationships of these complexes with MYC family members, as well as their future potential as therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.